On November 6, 2026, a clinical trial update was recorded for a study titled "Thymosin Alpha 1 and IgM Levels in Sepsis." The trial, registered as NCT07922954, is listed as Phase 4. Its current status is active, not recruiting, meaning the study is ongoing but no longer enrolling new participants.
Thymosin alpha-1 remains classified as an unapproved compound for research purposes. This trial update does not report any results, outcomes, or findings related to IgM levels, sepsis management, or patient response. It reflects only the recruitment and status change as registered on clinicaltrials.gov.
No efficacy, safety, or benefit conclusions can be drawn from a status update alone. The classification of the trial as Phase 4 indicates it is examining the compound in a post-marketing or late-stage research context relevant to its studied indication, but this does not confirm approval for the sepsis-related use being studied. Further updates may be posted as the trial progresses toward completion or results reporting.
Readers interested in background on this compound can consult the compound overview for additional context.